Literature DB >> 25448882

Two decades of publishing excellence in pharmaceutical biotechnology.

David B Volkin1, Susan Hershenson, Rodney J Y Ho, Susumu Uchiyama, Gerhard Winter, John F Carpenter.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25448882      PMCID： PMC4826475          DOI： 10.1002/jps.24285

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN： 0022-3549            Impact factor:   3.534


× No keyword cloud information.
  12 in total

1.  2011 FDA drug approvals.

Authors:  Asher Mullard
Journal:  Nat Rev Drug Discov       Date:  2012-02-01       Impact factor: 84.694

Review 2.  Development trends for human monoclonal antibody therapeutics.

Authors:  Aaron L Nelson; Eugen Dhimolea; Janice M Reichert
Journal:  Nat Rev Drug Discov       Date:  2010-09-03       Impact factor: 84.694

Review 3.  An industry perspective on the monitoring of subvisible particles as a quality attribute for protein therapeutics.

Authors:  Satish K Singh; Nataliya Afonina; Michel Awwad; Karoline Bechtold-Peters; Jeffrey T Blue; Danny Chou; Mary Cromwell; Hans-Juergen Krause; Hanns-Christian Mahler; Brian K Meyer; Linda Narhi; Doug P Nesta; Thomas Spitznagel
Journal:  J Pharm Sci       Date:  2010-08       Impact factor: 3.534

4.  Potential inaccurate quantitation and sizing of protein aggregates by size exclusion chromatography: essential need to use orthogonal methods to assure the quality of therapeutic protein products.

Authors:  John F Carpenter; Theodore W Randolph; Wim Jiskoot; Daan J A Crommelin; C Russell Middaugh; Gerhard Winter
Journal:  J Pharm Sci       Date:  2010-05       Impact factor: 3.534

5.  Disassembly and reassembly of yeast-derived recombinant human papillomavirus virus-like particles (HPV VLPs).

Authors:  Henryk Mach; David B Volkin; Robert D Troutman; Bei Wang; Zheng Luo; Kathrin U Jansen; Li Shi
Journal:  J Pharm Sci       Date:  2006-10       Impact factor: 3.534

6.  2012 FDA drug approvals.

Authors:  Asher Mullard
Journal:  Nat Rev Drug Discov       Date:  2013-02       Impact factor: 84.694

7.  2013 FDA drug approvals.

Authors:  Asher Mullard
Journal:  Nat Rev Drug Discov       Date:  2014-02       Impact factor: 84.694

8.  Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α.

Authors:  David J Shealy; Ann Cai; Kim Staquet; Audrey Baker; Eilyn R Lacy; Laura Johns; Omid Vafa; George Gunn; Susan Tam; Sarah Sague; Dana Wang; Mike Brigham-Burke; Paul Dalmonte; Eva Emmell; Bill Pikounis; Peter J Bugelski; Honghui Zhou; Bernard J Scallon; Jill Giles-Komar
Journal:  MAbs       Date:  2010-07-01       Impact factor: 5.857

9.  Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality.

Authors:  John F Carpenter; Theodore W Randolph; Wim Jiskoot; Daan J A Crommelin; C Russell Middaugh; Gerhard Winter; Ying-Xin Fan; Susan Kirshner; Daniela Verthelyi; Steven Kozlowski; Kathleen A Clouse; Patrick G Swann; Amy Rosenberg; Barry Cherney
Journal:  J Pharm Sci       Date:  2009-04       Impact factor: 3.534

10.  Marketed therapeutic antibodies compendium.

Authors:  Janice M Reichert
Journal:  MAbs       Date:  2012-04-26       Impact factor: 5.857
View more
  2 in total

1.  Impact of Glycosylation on the Local Backbone Flexibility of Well-Defined IgG1-Fc Glycoforms Using Hydrogen Exchange-Mass Spectrometry.

Authors:  Apurva S More; Ronald T Toth; Solomon Z Okbazghi; C Russell Middaugh; Sangeeta B Joshi; Thomas J Tolbert; David B Volkin; David D Weis
Journal:  J Pharm Sci       Date:  2018-05-08       Impact factor: 3.534

2.  High-throughput screening of antibody variants for chemical stability: identification of deamidation-resistant mutants.

Authors:  Danielle M DiCara; Nisana Andersen; Ruby Chan; James A Ernst; Gai Ayalon; Greg A Lazar; Nicholas J Agard; Amy Hilderbrand; Isidro Hötzel
Journal:  MAbs       Date:  2018-09-11       Impact factor: 5.857
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.